In many phase III clinical trials, particularly in the field of cancer, the comparison of treatments is based on both length of survival and quality of life. Subjects are followed over time until death and during this period, quality of life is assessed on a number of occasions. Simultaneous analysis of these two outcomes supplements the comparison of treatments in terms of each outcome independently with an assessment of the net effect. In addition, it provides a means of accounting for the informative dropout due to death of patients within the time frame of the quality of life study. The methods also have the potential to be extended to allow for informative dropout from the quality of life study prior to death. There are a number of broad approaches for the simultaneous analysis of quality of life and survival data. The most widely used approach in clinical research is quality-adjusted survival analysis, where treatments are compared in terms of a composite measure of quality and quantity of life. The paper reviews the different techniques for quality-adjusted survival analysis, illustrating the methodology by application to data from a phase III clinical trial in pancreatic cancer. In addition, alternative approaches using multistate survival analysis and joint modelling methods are also discussed.
Get full access to this article
View all access options for this article.
References
1.
Bowling A.Measuring health: a review of quality of life measurement scales. Milton Keynes: Open University Press , 1991.
2.
Beacon HJ , Thompson S.Multi-level models for repeated measurement data: application to quality of life data in clinical trials . Statistics in Medicine1996; 15: 2717-2732 .
Gelber RD , Goldhirsch A.A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer . Journal of Clinical Oncology1986; 4: 1772-1779 .
7.
Goldhirsch A , Gelber RD , Simes RJ , Glasziou P , Coates AS.Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis . Journal of Clinical Oncology1989; 7: 36-44 .
8.
Gelber RD , Cole BF , Gelber S , Goldhirsch A.Comparing treatments using quality-adjusted survival: the Q-TWiST method . American Statistician1995; 49: 161-169 .
9.
Glasziou PP , Cole BF , Gelber RD , Hilden J , Simes RJ.Quality adjusted survival analysis with repeated quality of life measures . Statistics in Medicine1998; 17: 1215-1229 .
10.
Aaronson NK , Ahmedzai S , Bergman Bet al.The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology . Journal of the National Cancer Institute1993; 85: 365-376 .
11.
Ganiats TGet al.Comparing the quality-adjusted life-year output of two treatment arms in a randomised trial . Medical Care1995; 33: AS245-AS254 .
12.
Korn EL.On estimating the distribution function for quality of life in cancer clinical trials . Biometrika1993; 80: 535-542 .
13.
Diggle PJ , Liang K , Zeger SL.Analysis of longitudinal data. Oxford: Clarendon Press , 1994.
14.
Fayers PM , Machin D.Quality of life: assessment, analysis and interpretation. John Wiley: Chichester , 2000.
15.
Billingham LJ , Abrams KR , Jones DR.Methods for the analysis of quality-of-life and survival data in health technology assessment . Health Technology Assessment1999; 3 (10): 1-152 .
16.
Hwang JS , Tsauo JY , Wang JD.Estimation of expected quality adjusted survival by cross-sectional survey . Statistics in Medicine1996; 15: 93-102 .
17.
Beacon HJ. The statistical analysis of self assessed quality of life data in cancer clinical trials, PhD thesis. London School of Hygiene and Tropical Medicine, University of London, 1996.
18.
Lin DY , Feuer EJ , Etzioni R , Wax Y.Estimating medical costs from incomplete follow-up data . Biometrics1997; 53: 419-434 .
19.
Efron B , Tibshirani RJ.An introduction to the bootstrap. San Francisco, CA: Chapman and Hall , 1993.
20.
Cox DR , Fitzpatrick R , Fletcher AE , Gore SM , Spiegelhalter DJ , Jones DR.Quality-of-life assessment: can we keep it simple?Journal of the Royal Statistical Society (A)1992; 155: 353-393 .
21.
Olschewski M , Schumacher M.Statistical analysis of quality of life data in cancer clinical trials . Statistics in Medicine1990; 9: 749-763 .
22.
Kay R.Multistate survival analysis: an application in breast cancer . Methods of Information in Medicine1984; 23: 157-162 .
23.
Hansen BE , Thorogood J , Hermans J , Ploeg RJ , van Bockel JH , van Houwelingen JC.Multistate modeling of liver transplantation data . Statistics in Medicine1994; 13: 2517-2529 .
24.
Andersen PK.Multistate models in survival analysis: a study of nephropathy and mortality in diabetes . Statistics in Medicine1988; 7: 661-670 .
25.
Marshall G , Jones RH.Multistate models and diabetic retinopathy . Statistics in Medicine1995; 14: 1975-1983 .
26.
Gentleman RC , Lawless JF , Lindsey JC , Yan P.Multistate Markov models for analyzing incomplete disease history data with illustrations for HIV disease . Statistics in Medicine1994; 13: 805-821 .
27.
Kay R.The analysis of transition times in multistate stochastic processes using proportional hazard regression models . Communications in Statistics—Theory and Methodology1982; 11: 1743-1756 .
28.
Andersen PK , Borgan O , Gill RD , Keiding N.Statistical Models Based on Counting Processes. New York: Springer , 1993.
29.
Henderson R , Diggle P , Dobson A.Joint modelling of longitudinal measurements and event time data . Biostatistics2000; 1: 465-480 .
30.
Hogan JW , Laird NM.Mixture models for the joint distribution of repeated measures and event times . Statistics in Medicine1997; 16: 239-257 .
31.
Hogan JW , Laird NM.Model-based approaches to analysing incomplete longitudinal and failure time data . Statistics in Medicine1997; 16: 259-272 .
32.
Wulfsohn MS , Tsiatis AA.A joint model for survival and longitudinal data measured with error . Biometrics1997; 53: 330-339 .
33.
Ribaudo HJ , Thompson SG , Allen-Mersh TG.A joint analysis of quality of life and survival using a random effect selection model . Statistics in Medicine2000; 19: 3237-3250 .
34.
Schluchter MD.Methods for the analysis of informatively censored longitudinal data . Statistics in Medicine1992; 11: 1861-1870 .
35.
Fairclough DL , Peterson HF , Cella Det al.Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials . Statistics in Medicine1998; 17: 781-796 .
36.
Shih WJ , Quan H.Testing for treatment differences with dropouts present in clinical trials—a composite approach . Statistics in Medicine1997; 16: 1225-1239 .
37.
Faucett CL , Thomas DC.Simultaneously modelling censored survival data and repeatedly measured covariates: a Gibbs sampling approach . Statistics in Medicine1996; 15: 1663-1685 .
38.
Berzuini C.Medical monitoring. In: Gilks WR , Richardson S , Spiegelhalter DJ , eds. Markov chain Monte Carlo in practice, Chap 18. London: Chapman and Hall , 1995.
39.
Xu J , Zeger SL.Joint analysis of longitudinal data compromising repeated measures and time to events . Applied Statistics2001; 50: 375-387 .
40.
Ganiats TG , Browner DK , Kaplan RM.Comparison of two methods of calculating quality-adjusted life years . Quality of Life Research1996; 5: 162-164 .
41.
Qian W , Parmar MKB , Sambrook RJ , Fayers PM , Girling DJ , Stephens RJ.Analysis of messy longitudinal data from a randomized clinical trial . Statistics in Medicine2000; 19: 2657-2674 .
42.
Kay R.A Markov model for analysing cancer markers and disease states in survival studies . Biometrics1986; 42: 855-865 .
43.
Lambert PC , Abrams KR , Sanso B , Jones DR.Synthesis of incomplete data using Bayesian hierarchical models: an illustration based on data describing survival from neuroblastoma, Technical Report 93-03. University of Leicester, Epidemiology and Public Health , 1999.
